Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the magnitude and clinical relevance of a
potential drug-drug interaction of GSK3882347 with midazolam (MDZ) in healthy participants.
This study assesses the effect of GSK3882347 as an inducer of Cytochrome P450 3A4 (CYP3A4)
using MDZ, a sensitive substrate of hepatic and intestinal CYP3A4. The study will investigate
MDZ pharmacokinetic (PK) effect in two dosing periods:
Period 1: A single dose of MDZ Period 2: 14-days of once daily repeat dosing of GSK3882347
followed by single dose of MDZ co-administered with GSK3882347 on Day 15 (14-days has been
selected as this duration is required in order to maximize any potential CYP3A4 enzyme
induction).